RecruitingNot ApplicableNCT06786390

Improved Recovery of Walking in Acquired Muscle Weakness

Regaining Walking Ability Easier and Better in Critical Illness Polyneuropathy and Myopathy


Sponsor

Fondazione Don Carlo Gnocchi ETS

Enrollment

72 participants

Start Date

Feb 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of Re-Walk-Easy is to evaluate the effects of rehabilitation based on electrical stimulation on the motor performance of critically ill patients. The study will also investigate the pathophysiology of the two forms-the myopathic-predominant and the polyneuropathic-predominant variants-by examining the longitudinal progression of CIP and CIM and determining which form benefits more from electrical stimulation as a rehabilitative approach.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Rehabilitation protocol without FES, Rehabilitation protocol: FES, and others for people with critical illness myopathy and critical illness polyneuropathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRehabilitation protocol: FES

Subjects diagnosed with CIP will follow the FES-based rehabilitation protocol

OTHERRehabilitation protocol without FES

Subjects belonging to the control group will follow the rehabilitation protocol without FES

OTHERRehabilitation protocol: FES

Subjects diagnosed with CIM will follow the FES-based rehabilitation protocol


Locations(1)

IRCCS Fondazione Don Carlo Gnocchi Onlus

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06786390


Related Trials